Telbivudine
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
Telbivudine: Chronic hepatitis C virus infection
One-Sentence Summary
Telbivudine is an oral nucleoside analogue originally used to treat chronic hepatitis B virus (HBV) infection. The TxGNN model predicts it may be effective for chronic hepatitis C virus infection, but this is currently a model-only prediction, with 0 clinical trials and 6 publications, none of which report telbivudine activity against hepatitis C virus (HCV).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Chronic hepatitis C virus infection |
| TxGNN Prediction Score | 0.9996 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (2 of 2) – CDSCO approval status is not included in this data |
| Number of Listed Products | 2 (valid: 2) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Published literature describes telbivudine as a thymidine nucleoside analogue that selectively inhibits HBV DNA polymerase. Its efficacy in chronic hepatitis B is well established.
The mechanistic link to hepatitis C is weak. HCV replicates through an RNA-dependent RNA polymerase (NS5B), which differs structurally and functionally from HBV DNA polymerase. HCV is now treated with direct-acting antivirals. The high score most likely reflects similarities the TxGNN model (deep learning) learned between related diseases, since both are chronic viral hepatitis, not biological evidence. It does not reflect demonstrated antiviral activity.
The retrieved literature supports this reading. Most papers are reviews covering both hepatitis B and C, and none shows telbivudine acting against HCV.
Hepatitis B itself appears as the second-ranked prediction. This is the approved indication, with Phase 3 and Phase 4 trials, and it acts as a positive control for the model rather than a true repurposing finding.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 25233195 | 2014 | Review | J Perinatol | Hepatitis B and C in pregnancy and efforts to reduce mother-to-child transmission. No telbivudine-specific HCV data. |
| 25027705 | 2014 | Review | Minerva Gastroenterol Dietol | Effects of hepatitis B and C antiviral drugs, including telbivudine for hepatitis B, on kidney function. |
| 16937041 | 2006 | Review | Wien Med Wochenschr | Current and future treatment of chronic hepatitis B and C, mainly interferon and lamivudine. |
| 18340426 | 2008 | Review | Der Internist | German recommendations for antiviral therapy of hepatitis B and C. Telbivudine is listed as an option for hepatitis B only. |
| 21999649 | 2011 | Review | Paediatr Drugs | Management of chronic liver disease in children, including viral hepatitis. |
| 23697556 | 2013 | Cohort | J Interferon Cytokine Res | Serum IL-37 levels and HBeAg seroconversion in HBV patients on telbivudine. HBV-specific, not HCV. |
India Market Information
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| 223925 | Telbihep 600mg Tablet | Strip of 10 tablets (oral) | Zydus Cadila |
| 203070 | Sebivo 600mg Tablet | Strip of 15 tablets (oral) | Novartis India Ltd |
Both are valid single-ingredient registrations.
Safety Considerations
- Conditions flagged as contraindication-related: kidney disease, pyoureter, myopathy, muscular disease, skeletal muscle disease, familial periodic paralysis, peripheral nervous system disease, peripheral neuropathy, fatty liver disease, non-alcoholic steatohepatitis, lactic acidosis, dermatomyositis, myositis. These come from drug-disease relationship data, not from package insert text.
- Drug interactions: 96 interacting drugs are recorded. The 20 listed in the data are all rated Moderate. They include:
- corticosteroids (hydrocortisone, prednisone, dexamethasone, betamethasone, budesonide, triamcinolone)
- amphotericin B formulations
- aminoglycosides and other antibiotics (kanamycin, neomycin, vancomycin, metronidazole)
- statins (rosuvastatin, simvastatin)
- aminosalicylates (mesalazine, sulfasalazine, balsalazide, olsalazine)
- orlistat
Package insert warnings were not available. Please refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on model score. There are no clinical trials, no plausible mechanism (HBV DNA polymerase versus HCV NS5B), and no literature showing activity against HCV. Effective direct-acting antivirals already exist for hepatitis C. The neuromuscular and renal safety signals add further caution.
To proceed, the following is needed:
- In vitro HCV replicon or enzyme data showing any telbivudine activity against HCV
- Detailed mechanism of action data
- Package insert warnings and contraindications from the India registrations
- A clear comparison against current direct-acting antiviral regimens to justify any clinical development
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.